Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 4
2002 4
2003 4
2004 2
2005 9
2006 4
2007 11
2008 1
2009 10
2010 4
2011 4
2012 1
2013 5
2014 1
2015 9
2016 8
2017 7
2018 7
2019 5
2020 6
2021 3
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 32245896

102 results

Results by year

Filters applied: . Clear all
Page 1
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A. Stokke C, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1233-1241. doi: 10.1007/s00259-018-3964-9. Epub 2018 Feb 22. Eur J Nucl Med Mol Imaging. 2018. PMID: 29470615 Free PMC article. Clinical Trial.
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H. Kolstad A, et al. Blood Adv. 2020 Sep 8;4(17):4091-4101. doi: 10.1182/bloodadvances.2020002583. Blood Adv. 2020. PMID: 32877524 Free PMC article. Clinical Trial.
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest.
Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, Jarlier M, Bonnefoy N, Patzke S, Stenberg V, Coopman P, Cartron G, Navarro-Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Bardiès M, Pouget JP. Pichard A, et al. Leukemia. 2020 May;34(5):1315-1328. doi: 10.1038/s41375-019-0677-4. Epub 2019 Dec 13. Leukemia. 2020. PMID: 31836849 Free PMC article.
High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jäger D, Haberkorn U, Arndt MA, Krauss J. Weber T, et al. Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):489-98. doi: 10.1007/s00259-015-3175-6. Epub 2015 Sep 4. Eur J Nucl Med Mol Imaging. 2016. PMID: 26341366
102 results